No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
1 |
rs183698338 |
chr2:50914067-50914068 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
2 |
rs561390952 |
chr2:50914083-50914084 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
3 |
rs531678321 |
chr2:50914106-50914107 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
4 |
rs550184833 |
chr2:50914111-50914112 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
5 |
rs571546367 |
chr2:50914166-50914167 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
6 |
rs532880348 |
chr2:50914169-50914170 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
7 |
rs550089223 |
chr2:50914178-50914179 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
8 |
rs547693747 |
chr2:50914190-50914191 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
9 |
rs565985699 |
chr2:50914207-50914208 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
10 |
rs537686983 |
chr2:50914225-50914226 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
11 |
rs554705457 |
chr2:50914242-50914243 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
12 |
rs370971377 |
chr2:50914291-50914292 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
13 |
rs188840950 |
chr2:50914303-50914304 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
14 |
rs570342888 |
chr2:50914307-50914308 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
15 |
rs191775670 |
chr2:50914334-50914335 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
16 |
rs532664864 |
chr2:50914340-50914341 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
17 |
rs185185811 |
chr2:50914344-50914345 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
18 |
rs553308018 |
chr2:50914359-50914360 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
19 |
rs551358321 |
chr2:50914364-50914365 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
20 |
rs574757790 |
chr2:50914410-50914411 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
21 |
rs542062637 |
chr2:50914458-50914459 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
22 |
rs375503548 |
chr2:50914474-50914475 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
23 |
rs563458731 |
chr2:50914479-50914480 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
24 |
rs918808 |
chr2:50914485-50914486 |
Enhancers Weak transcription
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
25 |
rs190080090 |
chr2:50914518-50914519 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
26 |
rs543541564 |
chr2:50914570-50914571 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
27 |
rs565340048 |
chr2:50914585-50914586 |
Enhancers Weak transcription
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
28 |
rs532404828 |
chr2:50914629-50914630 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
29 |
rs371340334 |
chr2:50914635-50914636 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
30 |
rs533164152 |
chr2:50914648-50914649 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
31 |
rs556034252 |
chr2:50914650-50914651 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
32 |
rs182195943 |
chr2:50914668-50914669 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
33 |
rs149756154 |
chr2:50914671-50914672 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
34 |
rs371970348 |
chr2:50914684-50914685 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
35 |
rs147430002 |
chr2:50914729-50914730 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
36 |
rs530312142 |
chr2:50914784-50914785 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
37 |
rs187269696 |
chr2:50914793-50914794 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
38 |
rs114566606 |
chr2:50914826-50914827 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
39 |
rs533728993 |
chr2:50914839-50914840 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
40 |
rs369545303 |
chr2:50914844-50914845 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
41 |
rs189248900 |
chr2:50914854-50914855 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
42 |
rs180974392 |
chr2:50914862-50914863 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
43 |
rs139901070 |
chr2:50914864-50914865 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
44 |
rs534343972 |
chr2:50914876-50914877 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
45 |
rs552970917 |
chr2:50914898-50914899 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
46 |
rs185036844 |
chr2:50914935-50914936 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
47 |
rs535727035 |
chr2:50915094-50915095 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
48 |
rs553956520 |
chr2:50915139-50915140 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
49 |
rs577862260 |
chr2:50915144-50915145 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
50 |
rs557232594 |
chr2:50915172-50915173 |
Enhancers Weak transcription Flanking Active TSS Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|